Nutritional Requirement for the Severe Trauma Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Suk-Kyung Hong, MD., PhD.
- Phone Number: 82-2-3010-5989
- Email: skhong94@amc.seoul.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 138-736
- Recruiting
- Asan Medical Center
-
Contact:
- Suk-Kyung Hong, MD., PhD.
- Phone Number: 82-2-3010-5989
- Email: skhong94@amc.seoul.kr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ISS more than 15 score
- older than 20 years old
- patient who need parenteral nutrition more than 5 days
Exclusion Criteria:
- patients who have metabolic disease except for diabetes
- patients who cannot resuscitated
- very low body weight (< 40kg)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: low calory
15kcal/kg caloric supplement
|
high caloric nutritional supplement (25kcal/kg)
|
|
Active Comparator: high calory
25kcal/kg
|
low caloric nutritional supplement(15kcal/kg)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of antibiotics usage (days)
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 week).
|
participants will be followed for the duration of hospital stay, an expected average of 2 week).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mortality
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 week
|
participants will be followed for the duration of hospital stay, an expected average of 2 week
|
|
Number of date when is showing hyperglycemia (more than 200mg/dL)
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 week
|
participants will be followed for the duration of hospital stay, an expected average of 2 week
|
|
Hospitals stays
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 week
|
participants will be followed for the duration of hospital stay, an expected average of 2 week
|
|
ICU stays
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 week
|
participants will be followed for the duration of hospital stay, an expected average of 2 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Suk-Kyung Hong, MD, PhD., Asan Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012-001 (Other Grant/Funding Number: Meriter Hospital)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.